Study shows promise of new anti-KRAS drug for pancreatic cancer



Study shows promise of new anti-KRAS drug for pancreatic cancer

A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers showed.

Materials provided by University of Pennsylvania School of Medicine. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

1st June 2023

Open-analysis platform for pediatric brain tumors provides robust data resource for childhood cancer research

Read more
31st May 2023

Plants remove cancer causing toxins from air

Read more
31st May 2023

How the flu virus hacks our cells

Read more